Analysis of efficacy and factors influencing sequential combination therapy with tenofovir alafenamide fumarate after treatment with entecavir in chronic hepatitis B patients with low-level viremia

Objective To observe the efficacy and factors influencing sequential or combined tenofovir alafenamide fumarate(TAF)after treatment with entecavir(ETV)in patients with chronic hepatitis B(CHB)with low-level viremia(LLV).Methods 126 CHB cases treated with ETV antiviral therapy in the Department of Infectious Diseases of the First Affiliated Hospital of Nanchang University from January 2020 to September 2022 were retrospectively collected.